Literature DB >> 15297287

The mystery of PCSK9.

Alan D Attie.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297287     DOI: 10.1161/01.ATV.0000137288.82390.04

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


× No keyword cloud information.
  6 in total

1.  [Orphan drugs].

Authors:  Jürgen R Schäfer; Claus F Vogelmeier
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

Review 2.  The proprotein convertases are potential targets in the treatment of dyslipidemia.

Authors:  Nabil G Seidah; Annik Prat
Journal:  J Mol Med (Berl)       Date:  2007-03-10       Impact factor: 4.599

3.  A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.

Authors:  Suet N Chen; Christie M Ballantyne; Antonio M Gotto; Yanli Tan; James T Willerson; Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2005-04-21       Impact factor: 24.094

4.  PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

Authors:  Mary Cabell Jonas; Claudio Costantini; Luigi Puglielli
Journal:  EMBO Rep       Date:  2008-07-25       Impact factor: 8.807

Review 5.  Lysine acetylation in the lumen of the ER: a novel and essential function under the control of the UPR.

Authors:  Mariana Pehar; Luigi Puglielli
Journal:  Biochim Biophys Acta       Date:  2012-12-13

6.  Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats.

Authors:  Lianqun Jia; Nan Song; Guanlin Yang; Yixin Ma; Xuetao Li; Ren Lu; Huimin Cao; Ni Zhang; Meilin Zhu; Junyan Wang; Xue Leng; Yuan Cao; Ying Du; Yue Xu
Journal:  Mol Med Rep       Date:  2016-04-14       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.